87% of rare disease and specialty therapy manufacturers are already using Artificial Intelligence and Machine Learning tools at some point in the commercialization stage. These tools help speed the identification of patients, identify a more diverse patient sample and locate patients in rural areas. AI and ML can also help manufacturers evaluate the commercial effectiveness of new products.

While adoption is high, manufacturers are missing potential opportunities to use AI and ML for patient identification. AI and ML can help locate treating physicians, prescribers, and other thought leaders; these stakeholders play a major role in patient identification. And, surprisingly, only 34% of manufacturers report using AI and ML to identify undiagnosed and misdiagnosed patients. In this research report you’ll learn:

• How AI and ML can help speed new therapies to market
• What to look for when choosing an AI/ML vendor
• How to identify and engage with patients and other care stakeholders

​